Immunovant announces $450M PIPE at $20/share to advance pipeline

Immunovant, Inc.

Agreed to sell 22.5M shares at $20/share to three institutional investors, including Roivant Sciences.
Gross proceeds expected ~$450M; closing on or about Jan 15, 2025 subject to customary conditions.
Proceeds to fund development pipeline (lead asset IMVT-1402), working capital, and general corporate purposes.
Shares sold in private placement exempt from registration; resale registration to be filed with SEC.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.